Concert Pharmaceuticals, Inc. – NASDAQ:CNCE

Market open

Closed in about 3 hours

+72.22%

quarter

+201.08%

year

Market Cap	N/A
Enterprise value	335.27M

P/E	-2.64
EV/Sales	5925.84
EV/EBITDA	-5.05
Price/Sales	7357.07
Price/Book	3.12
PEG ratio	-0.02
EPS	-1.53

Revenue	N/A
EBITDA	-68.59M
Income	-66.45M
Revenue Q/Q	-98.52%
Revenue Y/Y	-99.82%

Profit margin	-119465.25%
Oper. margin	-219641.91%
Gross margin	37.12%
EBIT margin	-219641.91%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE): Profit margin
Dec 2021	27.57K	22.58M	81909.31%
Mar 2022	0	-39.42M
Jun 2022	21K	-21.41M	-101966.67%
Sep 2022	8K	-28.20M	-352525%

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE): Earnings per share (EPS)
2022-11-07	-0.59	-0.58
2023-03-02	-0.59	-0.95

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE): Debt to assets
Dec 2021	165316000	53.09M	32.11%
Mar 2022	129411000	52.84M	40.84%
Jun 2022	176393000	48.60M	27.55%
Sep 2022	171134000	37.86M	22.12%

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE): Cash Flow
Dec 2021	-26.47M	-16K	64.46M
Mar 2022	-32.32M	-49.94M	0
Jun 2022	-24.90M	34.93M	69.85M
Sep 2022	-25.95M	-39.09M	20.99M

Concert Pharmaceuticals alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Concert Pharmaceuticals
Employees

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE): Employee count
Aug 2023	64
Sep 2023	64
Oct 2023	64
Nov 2023	64
Dec 2023	64
Jan 2024	64
Feb 2024	64
Mar 2024	64
Apr 2024	64
May 2024	64
Jun 2024	64
Jul 2024	64

Concert Pharmaceuticals
Insider Trading

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE): Insider trades (number of shares)
Period	Buy	Sel
Jun 2022	227052	0
Oct 2022	0	3539
Jan 2023	0	61104
Feb 2023	0	17334

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	15 Feb 2023	BECKER MARC A. officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	3,762	$8.33	$31,337
Sale	15 Feb 2023	CASSELLA JAMES V officer: Chief De..	Common Stock	3,762	$8.34	$31,375
Sale	15 Feb 2023	MUNSIE JEFFREY A officer: Chief Legal Officer officer: Chief Legal Officer	Common Stock	3,762	$8.34	$31,375
Sale	15 Feb 2023	STUART NANCY officer: Chief Operating Officer officer: Chief Operating Officer	Common Stock	6,048	$8.33	$50,380
Sale	30 Jan 2023	MUNSIE JEFFREY A officer: Chief Legal Officer officer: Chief Legal Officer	Common Stock	8,493	$8.35	$70,917
Sale	30 Jan 2023	STUART NANCY officer: Chief Operating Officer officer: Chief Operating Officer	Common Stock	13,200	$8.35	$110,220
Sale	30 Jan 2023	BECKER MARC A. officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	8,493	$8.35	$70,917
Sale	30 Jan 2023	CASSELLA JAMES V officer: Chief De..	Common Stock	10,106	$8.35	$84,385
Sale	6 Jan 2023	TUNG ROGER D director, officer..	Common Stock	9,240	$7.24	$66,898
Sale	6 Jan 2023	STUART NANCY officer: Chief Operating Officer officer: Chief Operating Officer	Common Stock	2,893	$7.25	$20,974

CNCE insider trading transactions

Concert Pharmaceuticals
Patents

Status	Patent	Filling date	Issue date
Application	Application METHODS OF TREATMENT WITH DEUTERATED ANALOGS OF D-SERINE Filling date: 29 May 2020 Issue date: 14 Jul 2022	29 May 2020	14 Jul 2022
Application	Application PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS Filling date: 12 Aug 2021 Issue date: 7 Jul 2022	12 Aug 2021	7 Jul 2022
Application	Application PROCESSES FOR THE PREPARATION OF DEUTERATED D-SERINE Filling date: 3 Apr 2020 Issue date: 2 Jun 2022	3 Apr 2020	2 Jun 2022
Application	Application 4-HYDROXYBUTYRIC ACID ANALOGS Filling date: 29 Oct 2021 Issue date: 26 May 2022	29 Oct 2021	26 May 2022
Grant	Grant Utility: Deuterated EPI-743 Filling date: 18 Nov 2016 Issue date: 8 Mar 2022	18 Nov 2016	8 Mar 2022
Application	Application COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY Filling date: 22 Feb 2021 Issue date: 27 Jan 2022	22 Feb 2021	27 Jan 2022
Application	Application 4-HYDROXYBUTYRIC ACID ANALOGS Filling date: 1 Feb 2021 Issue date: 30 Dec 2021	1 Feb 2021	30 Dec 2021
Application	Application NOVEL DEUTERATED JAK INHIBITOR AND USES THEREOF Filling date: 21 May 2021 Issue date: 16 Dec 2021	21 May 2021	16 Dec 2021
Application	Application Morphinan Compounds Filling date: 14 Dec 2020 Issue date: 11 Nov 2021	14 Dec 2020	11 Nov 2021
Grant	Grant Utility: 4-hydroxybutyric acid analogs Filling date: 10 Jan 2020 Issue date: 2 Nov 2021	10 Jan 2020	2 Nov 2021

CNCE patents

Concert Pharmaceuticals
Earnings Call Transcripts

Quarter	Transcript
Q3 2022 7 Nov 2022	Q3 2022 Earnings Call Transcript
Q2 2022 6 Aug 2022	Q2 2022 Earnings Call Transcript
Q1 2022 7 May 2022	Q1 2022 Earnings Call Transcript
Q4 2021 3 Mar 2022	Q4 2021 Earnings Call Transcript

CNCE earnings call transcripts

Concert Pharmaceuticals
Executives

Insider	Age	Compensation
Dr. Roger D. Tung (1960) Co-Founder, Chief Executive Officer, Pres & Executive Director	65	$914,160
Dr. James V. Cassella (1955) Chief Devel. Officer	70	$691,360
Mr. Richard H. Aldrich M.B.A., Mba (1954) Co-Founder & Chairman	71	$80,000

Concert Pharmaceuticals
Latest News

Thursday, 16 February 2023
13:54	Concert Pharmaceuticals: Negative Spread But Interesting CVR	Seeking Alpha
Monday, 23 January 2023
11:17	Concert (CNCE) Stock Up 17% Last Week on Sun Pharma Buyout Offer	Zacks Investment Research
Friday, 20 January 2023
18:15	Why Concert Pharmaceuticals Stock Rocketed Higher This Week	The Motley Fool
Monday, 7 November 2022
09:58	Concert Pharmaceuticals, Inc. (CNCE) Q3 2022 Earnings Call Transcript	Seeking Alpha
09:50	Concert Pharmaceuticals (CNCE) Reports Q3 Loss, Misses Revenue Estimates	Zacks Investment Research
Monday, 31 October 2022
07:00	Concert Pharmaceuticals to Report Third Quarter 2022 Results on November 7, 2022	Business Wire
Wednesday, 7 September 2022
10:32	Recent Price Trend in Concert (CNCE) is Your Friend, Here's Why	Zacks Investment Research
Monday, 22 August 2022
11:17	Wall Street Analysts Think Concert (CNCE) Could Surge 127%: Read This Before Placing a Bet	Zacks Investment Research
10:33	Recent Price Trend in Concert (CNCE) is Your Friend, Here's Why	Zacks Investment Research
Tuesday, 16 August 2022
13:33	Here's Why Concert Pharmaceuticals (CNCE) is a Great Momentum Stock to Buy	Zacks Investment Research
Saturday, 6 August 2022
10:50	Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q2 2022 Results - Earnings Call Transcript	Seeking Alpha
Friday, 5 August 2022
10:32	What Makes Concert (CNCE) a Good Fit for "Trend Investing"	Zacks Investment Research
Thursday, 4 August 2022
10:32	Concert Pharmaceuticals (CNCE) Reports Q2 Loss, Lags Revenue Estimates	Zacks Investment Research
Friday, 29 July 2022
07:00	Concert Pharmaceuticals to Report Second Quarter 2022 Results on August 4, 2022	Business Wire
Wednesday, 15 June 2022
11:48	Concert Pharmaceuticals: A Balanced Risk/Reward	Seeking Alpha
Friday, 13 May 2022
14:02	What's Going On With CCL Industries Shares Today	Benzinga
Saturday, 7 May 2022
13:56	Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q1 2022 Results - Earnings Call Transcript	Seeking Alpha
Tuesday, 26 April 2022
16:34	Earnings Preview: Concert Pharmaceuticals (CNCE) Q1 Earnings Expected to Decline	Zacks Investment Research
Thursday, 3 March 2022
11:07	Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q4 2021 Results - Earnings Call Transcript	Seeking Alpha
Monday, 3 January 2022
07:00	Concert Pharmaceuticals to Present at H.C. Wainwright BIOCONNECT Virtual Conference	Business Wire
Tuesday, 9 November 2021
13:42	Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q3 2021 Results - Earnings Call Transcript	Seeking Alpha
09:56	Concert Pharmaceuticals (CNCE) Reports Q3 Loss, Tops Revenue Estimates	Zacks Investment Research
Friday, 5 November 2021
16:01	Are These Trending Penny Stocks Worth Buying at Current Levels?	PennyStocks
Thursday, 4 November 2021
20:40	Concert Pharmaceuticals (CNCE) Stock: Why The Price Surged Today	Pulse2
13:25	Why These Penny Stocks Popped Today, 3 to Watch	PennyStocks
Thursday, 28 October 2021
16:49	Earnings Preview: Concert Pharmaceuticals (CNCE) Q3 Earnings Expected to Decline	Zacks Investment Research
Friday, 3 September 2021
07:00	Concert Pharmaceuticals to Present at Upcoming Investor Conferences	Business Wire

Ideas & Opinions

Seeking Alpha 16 Feb 2023

Concert Pharmaceuticals: Negative Spread But Interesting CVR
Seeking Alpha 15 Jun 2022

Concert Pharmaceuticals: A Balanced Risk/Reward

Frequently Asked Questions (FAQ)

When is Concert Pharmaceuticals's next earnings date?

Unfortunately, Concert Pharmaceuticals's (CNCE) next earnings date is currently unknown.
Does Concert Pharmaceuticals pay dividends?

No, Concert Pharmaceuticals does not pay dividends.
What is Concert Pharmaceuticals's stock symbol?

Concert Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "CNCE".
What is Concert Pharmaceuticals's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Concert Pharmaceuticals?

Shares of Concert Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Concert Pharmaceuticals's key executives?
Concert Pharmaceuticals's management team includes the following people:
- Dr. Roger D. Tung Co-Founder, Chief Executive Officer, Pres & Executive Director(age: 65, pay: $914,160)
- Dr. James V. Cassella Chief Devel. Officer(age: 70, pay: $691,360)
- Mr. Richard H. Aldrich M.B.A., Mba Co-Founder & Chairman(age: 71, pay: $80,000)
Is Concert Pharmaceuticals founder-led company?

Yes, Concert Pharmaceuticals is a company led by its founders Dr. Roger D. Tung and Mr. Richard H. Aldrich M.B.A., Mba.
How many employees does Concert Pharmaceuticals have?

As Jul 2024, Concert Pharmaceuticals employs 64 workers.
When Concert Pharmaceuticals went public?

Concert Pharmaceuticals, Inc. is publicly traded company for more then 11 years since IPO on 13 Feb 2014.
What is Concert Pharmaceuticals's official website?

The official website for Concert Pharmaceuticals is concertpharma.com.
Where are Concert Pharmaceuticals's headquarters?

Concert Pharmaceuticals is headquartered at 65 Hayden Avenue, Lexington, MA.
How can i contact Concert Pharmaceuticals?

Concert Pharmaceuticals's mailing address is 65 Hayden Avenue, Lexington, MA and company can be reached via phone at +7 818600045.

Concert Pharmaceuticals, Inc.

concertpharma.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

+7 818600045

65 Hayden Avenue
Lexington, MA 02421

CIK: 0001367920
ISIN: US2060221056
CUSIP: 206022105